Co-Authors
This is a "connection" page, showing publications co-authored by ABENAA BREWSTER and JENNIFER LITTON.
Connection Strength
0.723
-
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008 Sep 01; 26(25):4072-7.
Score: 0.323
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.173
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
Score: 0.061
-
Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.
Score: 0.053
-
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8.
Score: 0.031
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.030
-
The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012; 17(10):1240-5.
Score: 0.027
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.026